MX391363B - Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor. - Google Patents

Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor.

Info

Publication number
MX391363B
MX391363B MX2019006941A MX2019006941A MX391363B MX 391363 B MX391363 B MX 391363B MX 2019006941 A MX2019006941 A MX 2019006941A MX 2019006941 A MX2019006941 A MX 2019006941A MX 391363 B MX391363 B MX 391363B
Authority
MX
Mexico
Prior art keywords
relieve
prevent
carbamate compound
tremor syndrome
treat tremors
Prior art date
Application number
MX2019006941A
Other languages
English (en)
Spanish (es)
Other versions
MX2019006941A (es
Inventor
Han Ju Yi
Hye Sung Lee
Jin Uk Yoo
Original Assignee
Sk Biopharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sk Biopharmaceuticals Co Ltd filed Critical Sk Biopharmaceuticals Co Ltd
Publication of MX2019006941A publication Critical patent/MX2019006941A/es
Publication of MX391363B publication Critical patent/MX391363B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2019006941A 2016-12-14 2017-12-14 Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor. MX391363B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160170225 2016-12-14
PCT/KR2017/014743 WO2018111009A1 (ko) 2016-12-14 2017-12-14 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (2)

Publication Number Publication Date
MX2019006941A MX2019006941A (es) 2019-09-06
MX391363B true MX391363B (es) 2025-03-21

Family

ID=62558966

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006941A MX391363B (es) 2016-12-14 2017-12-14 Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el sindrome de temblor.

Country Status (13)

Country Link
US (1) US11033531B2 (enExample)
EP (1) EP3556364B1 (enExample)
JP (1) JP7086076B2 (enExample)
KR (1) KR102635941B1 (enExample)
CN (1) CN110267657B (enExample)
AU (1) AU2017374459B2 (enExample)
CL (1) CL2019001623A1 (enExample)
ES (1) ES3039979T3 (enExample)
IL (1) IL267191B2 (enExample)
MX (1) MX391363B (enExample)
MY (1) MY198417A (enExample)
WO (1) WO2018111009A1 (enExample)
ZA (1) ZA201903749B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2973111T3 (es) * 2017-11-14 2024-06-18 Sk Biopharmaceuticals Co Ltd Uso de un compuesto de carbamato para prevenir o tratar enfermedades asociadas con el aumento de la corriente tardía de sodio
IL281559B2 (en) * 2018-09-21 2025-06-01 Sk Biopharmaceuticals Co Ltd (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50676B (sr) * 2001-02-27 2010-06-30 Ortho-Mcneil Pharmaceutical Inc. Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
WO2005097136A1 (en) * 2004-03-29 2005-10-20 Merck & Co., Inc. Biaryl substituted pyrazinones as sodium channel blockers
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
EP2114393B1 (en) * 2007-03-05 2013-04-17 Indus Biotech Private Limited Pharmaceutical compositions comprising trigonelline and 4-hydroxyisoleucine and a process thereof
AU2009348523B2 (en) * 2009-06-22 2015-02-26 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
JP6062077B2 (ja) * 2013-03-12 2017-01-18 バイオ−ファーム ソリューションズ カンパニー リミテッド 小児てんかん及びてんかん関連症侯群の予防又は治療用フェニルカルバメート化合物｛ｐｈｅｎｙｌｃａｒｂａｍａｔｅｃｏｍｐｏｕｎｄｓｆｏｒｕｓｅｉｎｐｒｅｖｅｎｔｉｎｇｏｒｔｒｅａｔｉｎｇｐｅｄｉａｔｒｉｃｅｐｉｌｅｓｙａｎｄｅｐｉｌｅｓｙ−ｒｅｌａｔｅｄｓｙｎｄｒｏｍｅｓ｝
KR102489052B1 (ko) * 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Also Published As

Publication number Publication date
KR102635941B1 (ko) 2024-02-13
KR20190087573A (ko) 2019-07-24
MY198417A (en) 2023-08-29
RU2019121914A (ru) 2021-01-15
IL267191B1 (en) 2023-01-01
CN110267657A (zh) 2019-09-20
CA3046300A1 (en) 2018-06-21
MX2019006941A (es) 2019-09-06
CN110267657B (zh) 2022-12-13
CL2019001623A1 (es) 2019-08-23
EP3556364B1 (en) 2025-08-27
AU2017374459B2 (en) 2023-04-27
IL267191B2 (en) 2023-05-01
EP3556364A1 (en) 2019-10-23
JP2020502137A (ja) 2020-01-23
BR112019012000A2 (pt) 2019-10-29
RU2019121914A3 (enExample) 2021-04-21
ZA201903749B (en) 2022-01-26
US11033531B2 (en) 2021-06-15
EP3556364A4 (en) 2020-06-17
AU2017374459A1 (en) 2019-07-04
WO2018111009A1 (ko) 2018-06-21
ES3039979T3 (en) 2025-10-28
JP7086076B2 (ja) 2022-06-17
US20190336481A1 (en) 2019-11-07
IL267191A (enExample) 2019-07-31

Similar Documents

Publication Publication Date Title
DOP2019000117A (es) Nuevos derivados de quinolina
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
UY37789A (es) Nuevos derivados de azaquinolina
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
UY37831A (es) Nuevos derivados de quinolina
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
MX2016011810A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
MX2020004694A (es) Composiciones farmaceuticas inyectables de isoxazolina y su uso contra la infestacion de parasitos.
EA201991580A1 (ru) Пиримидиновое соединение и его фармацевтическое применение
MX2018014080A (es) Uso de compuesto de carbamato para prevenir o tratar fibromialgia o sindrome funcional asociado con fibromialgia.
MX382175B (es) Composiciones de profármaco de monometilfumarato
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2019004232A (es) Compuestos terapéuticos y métodos para utilizarlos.
MX2019012522A (es) Compuestos y metodos terapeuticos.
DOP2020000077A (es) Nuevo derivado de fenilpiridina y composición farmacéutica que lo contiene
MX2020004842A (es) Compuestos heterociclicos antiinfecciosos y sus usos.
CO2021001849A2 (es) Nuevo derivado de amina heterocíclico y composición farmacéutica que lo comprende
MX2017011682A (es) Mezcla plaguicida que comprende un compuesto de carboxamida y un bioplaguicida.
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
CL2019001623A1 (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar temblores o el síndrome de temblor.
CL2019001617A1 (es) Preparación líquida parenteral que comprende compuesto de carbamato.
MX2018014081A (es) Uso de compuesto de carbamato para prevenir o tratar neuralgia trigeminal.
MX2021004342A (es) Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia.
MX2021003203A (es) Compuesto de carbamato y uso de la formulacion que comprende el mismo en prevenir, aliviar, o tratar trastorno de estres agudo o trastorno de estres post-traumatico.
ECSP16095557A (es) Métodos para tratar infecciones